Did You Know?

Editor’s Picks

Latest News

Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

WestGene’s established targeted LNP platform combined with Cartesian’s mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid...

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09,...

Atavistik Bio Announces U.S. FDA Clearance of Investigational New Drug Application and Fast Track Designation for ATV-1601 for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

error: Content is protected !!